SAB Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . SAB Biotherapeutics
SABS Stock  USD 1.55  0.07  4.32%   
SAB Biotherapeutics financial statements provide useful quarterly and yearly information to potential SAB Biotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on SAB Biotherapeutics financial statements helps investors assess SAB Biotherapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting SAB Biotherapeutics' valuation are summarized below:
Gross Profit
-25.4 M
Market Capitalization
15 M
Enterprise Value Revenue
1.206
Revenue
1.5 M
Earnings Share
(6.30)
There are over one hundred nineteen available fundamental measures for SAB Biotherapeutics, which can be analyzed over time and compared to other ratios. All traders should double-check SAB Biotherapeutics' latest fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 41.5 M in 2025. Enterprise Value is likely to gain to about (13.8 M) in 2025

SAB Biotherapeutics Total Revenue

1.91 Million

Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Interest Income of 80.1 K, Depreciation And Amortization of 4.5 M or Interest Expense of 289.4 K, as well as many indicators such as Price To Sales Ratio of 18.54, Dividend Yield of 0.0 or PTB Ratio of 0.63. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of SAB Biotherapeutics Correlation against competitors.
For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

SAB Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets63.5 M96.5 M38.2 M
Slightly volatile
Short and Long Term Debt Total5.5 M5.3 M7.1 M
Slightly volatile
Other Current Liabilities8.2 M7.7 M3.6 M
Slightly volatile
Total Current Liabilities14.6 M12.4 M8.4 M
Slightly volatile
Property Plant And Equipment Net25.2 M28.4 M15.4 M
Slightly volatile
Accounts Payable808.8 K851.3 K2.5 M
Very volatile
Cash68.3 M65.1 M19.6 M
Slightly volatile
Non Current Assets Total25.4 M28.8 M15.5 M
Slightly volatile
Long Term Debt654 K622.9 K225.5 K
Slightly volatile
Cash And Short Term Investments68.3 M65.1 M19.6 M
Slightly volatile
Common Stock Shares Outstanding9.4 M5 M29 M
Slightly volatile
Liabilities And Stockholders Equity63.5 M96.5 M38.2 M
Slightly volatile
Non Current Liabilities Total9.4 M14.2 M14 M
Slightly volatile
Capital Lease Obligations4.8 M4.4 M5.9 M
Slightly volatile
Other Current Assets2.7 M2.7 M1.2 M
Slightly volatile
Other Stockholder Equity177.9 M169.4 M61.9 M
Slightly volatile
Total Liabilities27.5 M30.6 M22.9 M
Slightly volatile
Property Plant And Equipment Gross27.7 M39.8 M17.8 M
Slightly volatile
Short and Long Term Debt604.8 K945.8 K1.1 M
Slightly volatile
Total Current Assets38.1 M67.7 M22.7 M
Slightly volatile
Capital Stock7998414.2 K
Slightly volatile
Net Working Capital58.1 M55.3 M16.4 M
Slightly volatile
Short Term Debt1.9 M2.1 M1.9 M
Pretty Stable
Common Stock7948363.2 K
Slightly volatile
Property Plant Equipment23.4 M26.7 M14.8 M
Slightly volatile
Current Deferred Revenue1.6 M1.5 M358.7 K
Slightly volatile
Other Liabilities274.4 K288.8 K8.1 M
Slightly volatile
Non Currrent Assets Other299.4 K315.2 K5.1 M
Slightly volatile
Other Assets399.9 K420.9 K26.8 M
Slightly volatile
Common Stock Total Equity5.2 K5.9 K4.6 K
Slightly volatile
Capital Surpluse83.7 M97.1 M72.6 M
Slightly volatile
Deferred Long Term Liabilities274.4 K288.8 K8.1 M
Slightly volatile
Non Current Liabilities Other3.8 M3.6 M5 M
Slightly volatile
Accumulated Other Comprehensive Income21.1 K23.8 K25.9 K
Slightly volatile

SAB Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income80.1 K150.5 K100.8 K
Pretty Stable
Depreciation And Amortization4.5 M4.3 M1.4 M
Slightly volatile
Interest Expense289.4 K283.8 K389.9 K
Slightly volatile
Selling General Administrative15 M27.4 M9.2 M
Slightly volatile
Total Revenue1.9 M2 M11.3 M
Slightly volatile
Other Operating Expenses28.5 M46.4 M19.6 M
Slightly volatile
Research Development32.1 M19 M16.8 M
Slightly volatile
Total Operating Expenses27.6 M42.1 M19 M
Slightly volatile
Reconciled Depreciation4.5 M4.3 M1.2 M
Slightly volatile
Cost Of Revenue3.2 M4.3 M2.1 M
Slightly volatile
Selling And Marketing Expenses3 M3.4 M3.7 M
Slightly volatile

SAB Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation2 M2.8 M1.1 M
Slightly volatile
Begin Period Cash Flow13 M17.3 M12.6 M
Pretty Stable
Other Cashflows From Financing Activities81.1 M77.2 M19.6 M
Slightly volatile
Depreciation4.5 M4.3 M1.2 M
Slightly volatile
Capital Expenditures168.6 K177.4 K2.6 M
Slightly volatile
Total Cash From Financing Activities80.6 M76.8 M21.1 M
Slightly volatile
End Period Cash Flow34 M65.1 M19.4 M
Slightly volatile
Change To Inventory387.9 K436.4 K475.8 K
Slightly volatile
Change Receivables2.1 M2.2 M10 M
Slightly volatile
Cash Flows Other Operating788.1 K941 K671.4 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio18.5419.51805
Slightly volatile
Days Sales Outstanding15697.57225
Slightly volatile
Average Payables4.1 M2.7 M4.4 M
Slightly volatile
Stock Based Compensation To Revenue1.020.970.2703
Slightly volatile
Capex To Depreciation0.05750.06053.466
Pretty Stable
Payables Turnover3.743.561.0378
Slightly volatile
Sales General And Administrative To Revenue10.049.572.7017
Slightly volatile
Research And Ddevelopement To Revenue6.976.642.9535
Slightly volatile
Capex To Revenue0.07530.07920.18
Very volatile
Cash Per Share4.959.222.9028
Slightly volatile
Days Payables Outstanding101106782
Slightly volatile
Current Ratio5.154.92.6351
Slightly volatile
Receivables Turnover3.163.872.3831
Slightly volatile
Capex Per Share0.0390.04110.7367
Slightly volatile
Average Receivables3 M3.2 M11.7 M
Slightly volatile
Revenue Per Share0.440.473.2263
Slightly volatile
Interest Debt Per Share1.911.30.849
Slightly volatile
Debt To Assets0.07690.08090.301
Slightly volatile
Graham Number41.8647.151.3514
Slightly volatile
Operating Cycle15697.57225
Slightly volatile
Days Of Payables Outstanding101106782
Slightly volatile
Ebt Per Ebit1.111.271.0472
Pretty Stable
Total Debt To Capitalization0.10.110.9443
Slightly volatile
Quick Ratio5.154.92.6351
Slightly volatile
Net Income Per E B T1.121.151.0492
Pretty Stable
Cash Ratio4.944.712.007
Slightly volatile
Days Of Sales Outstanding15697.57225
Slightly volatile
Fixed Asset Turnover0.09910.10.5969
Pretty Stable
Debt Ratio0.07690.08090.301
Slightly volatile
Price Sales Ratio18.5419.51805
Slightly volatile
Asset Turnover0.02910.03070.2632
Pretty Stable

SAB Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap41.5 M43.7 M2.8 B
Slightly volatile

SAB Fundamental Market Drivers

Cash And Short Term Investments56.6 M

SAB Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
21st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About SAB Biotherapeutics Financial Statements

SAB Biotherapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although SAB Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in SAB Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on SAB Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.5 M1.6 M
Total Revenue2 M1.9 M
Cost Of Revenue4.3 M3.2 M
Stock Based Compensation To Revenue 0.97  1.02 
Sales General And Administrative To Revenue 9.57  10.04 
Research And Ddevelopement To Revenue 6.64  6.97 
Capex To Revenue 0.08  0.08 
Revenue Per Share 0.47  0.44 
Ebit Per Revenue(19.56)(18.58)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY